Mobile

An Open-label, Single Arm, Phase 2 Study of Rituximab, Gemcitabine, and Oxaliplatin plus Oral Enzastaurin as Treatment for Patients with Relapsed Diffuse Large B-Cell Lymphoma

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-001985-17

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Main objective : evaluation of progression free survival on R-GEMOX and enzastaurin, 1 year after treatment start, in patients with relapsed DLBCL or transformed (CD20+) indolent lymphoma, who are older than 60 years. Patients who are younger than 60 may be included if they are not eligible for HDC followed by ASCT

Critère d'inclusion

  • high-risk diffuse large B-cell lymphoma (DLBCL )

Liens